Aerogen has recently started its Indian sub-continent operation under the drive of international business expansion. Indian headquarter office is in Delhi at the 131-ABW Rectangle One Building, Saket-110017.
The entire new sales and distribution network of the organization is being re-structured for prompt support to users. Our operation in India will enable us to work more closely with customers and partners to meet their individual demands efficiently.
The organization has a strong international presence (over 75 countries) with offices in Ireland, U.K., France, Germany, China, the United States, India, and Middle-East, among others, and operates with 200 experienced staff worldwide. Over seven million patients have benefitted from Aerogen technology.
The presence of Aerogen System was very thin in India, and in view of high rise of respiratory-related conditions in the recent past, it becomes necessary to reach out and equip all healthcare centers with our system.
India is ranked as fourth most polluted country globally, where COPD and asthma are majorly due to tobacco smoke and rising level of environmental pollution in India. Air pollution cuts life by 4.3 years. A recent survey (Recent Life Expectancy Report) indicates that over 50 percent deaths in India are caused due to chronic diseases, where CLD is ranked second after cardiovascular disease.
India is witnessing a growing market for nebulizers, estimated at USD 67 million by 2023 from USD 8.2 million in 2014, at a CAGR of 26 percent. The vision for the technology has been to transform aerosol drug delivery for the most vulnerable patients in an acute care setting. There has been a long gap in the technological advancement of aerosol drug-delivery system; most of the nebulizers in use are those developed long back and have multiple limitations. Aerogen Ltd. perfected a way by developing vibrating mesh technology of turning liquid drugs into aerosols, and we became the first company in the world to develop an aerosol system that could deliver drugs effectively to respirators and neonates and pre-terms.
We apply our intelligence and expertise to create breakthroughs in new science for the greater good of patient care. We put patient’s needs at the heart of everything we do. It is our awareness and understanding of patient’s needs that allows us to take a holistic view of what is required from Aerogen in the marketplace.
Under our mission of awareness and education, we will make the healthcare providers aware about the Aerogen drug delivery system and its features like totally silent, versatile treatment with a quick, easy-to-set-up, easy to integrate without breaking the circuit, more medication delivery in half the time, precision technology giving deeper lung deposition, suitable for solutions, suspensions, proteins and peptides, and no heating or degradation of medication.
Aerogen is synonymous with better outcomes, and this guides us in everything we say and do and gives everyone a reason to believe in our brand:
- For healthcare professionals, Aerogen technology means a better standard of care;
- For patients, Aerogen means better treatment and a better quality of life;
- For talented engineers and professionals, Aerogen means a better career; and
- For distributors, Aerogen means discovering better business opportunities.
Aerogen Limited, Galway, Ireland, is a medical device and drug delivery company, which engages in the design, manufacture, and marketing of aerosol drug delivery systems. It offers a wide range of compact and single-patient Aerosol drug delivery system; solution for spontaneous breathing patients; nebulizer for treating mechanically ventilated patients; nebulizer enabling people to build their nebulizer treatments; a nebulizer for use in preclinical aerosol research and inhalation studies based on Vibronic (vibrating mesh technology), a high-performance aerosol technology.